secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2026-07-13T20:19:36+00:00
Accession:  0001193125-26-302045
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports 57% uORR at 8 weeks for ERAS-0015 in KRAS G12X PDAC; plans pivotal trials in 2027
--------------------------------------------------------------------------------

- 57% uORR at 8 weeks in 2L+ KRAS G12X PDAC at 32 mg QD RDE (N=7).
- Safety: mostly low-grade TRAEs, no DLTs, no discontinuations due to TRAEs; median relative dose intensity 100%.
- Combination with panitumumab in mCRC: no DLTs in 16 mg cohort; dose escalation ongoing.
- Plans: registration-enabling trial in NSCLC 2L+ in H1 2027; Phase 3 pivotal in PDAC 1L in 2027; Phase 3 pivotal in RAS-mutant NSCLC in H2 2027/H1 2028.
- One Grade 3 pneumonitis event progressed to Grade 5 after withdrawal of supportive care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526302045/0001193125-26-302045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526302045/d54726d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-302045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer